Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Antibodies × Head & Neck × Clear all

Phase

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4 Myeloid 4 Lymphoid 4 Gastrointestinal 3 Tumor-Agnostic 2 Dermatologic 2 Thoracic 1 Head & Neck 1 CNS 1 Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cisplatin 220 Radiotherapy 151 Cetuximab 136 Fluorouracil 89 Docetaxel 89 pembrolizumab 78 Radiotherapy, Intensity-Modulated 68 Paclitaxel 66 Carboplatin 66 Nivolumab 53 Erlotinib Hydrochloride 29 Gemcitabine 28 Surveys and Questionnaires 26 durvalumab 25 Radiation 25 Drug Therapy 22 Immunohistochemistry 21 Gefitinib 20 Capecitabine 18 Bevacizumab 17 tremelimumab 16 Ipilimumab 16 Surgical Procedures, Operative 14 Sorafenib 14 Pemetrexed 14 Magnetic Resonance Spectroscopy 14 Gene Expression Profiling 14 Afatinib 14 lenvatinib 13 atezolizumab 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02707588 2023-02-28

PembroRad

Groupe Oncologie Radiotherapie Tete et Cou

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon ⚡